Marksans' Relonchem Wins Approval for Ibuprofen, Paracetamol Tablets

According to Marksans Pharma, its subsidiary company, Relonchem, has received marketing authorization for Ibuprofen and Paracetamol, 200 mg/500 mg film-coated tablets. The products' intended purpose is to provide symptomatic relief of pain of mild to moderate intensity, e.g. migraines, headaches, backaches, menstrual pains, dental pain, rheumatic and muscular pains and cold or flu symptoms, sore throat, and fever.

The approval adds another milestone to the contribution towards strengthening Marksans Pharma's portfolio in pain management and in being a more competitive player in international markets.

Marksans Pharma operates in the research, manufacture, marketing, and selling of pharmaceutical formulations across nearly all major therapy segments. Its global reach spans well into the considered regulated markets of the United States, Europe, and Australia. The company's focus areas comprise over-the-counter (OTC) and prescription drugs committed to affordable quality solutions.

For the third quarter of FY25, the company is reported to be doing well, marking a gain of 25.6% in its consolidated net profit from the previous year's Rs. 1,04.56 crore with revenue from operations up 16.3%, or slightly exceeding Rs. 681.85 crore, corresponding to the third quarter of FY24. This shows how fast consumers were demanding its products due to the quality and successful expansion into new markets worldwide.

Strengthening Marksans in the pharmaceutical landscape has been this further registration with very lucrative quarterly results, with a definite focus on innovation and diversifying its product portfolio.